Mallinckrodt Presents Health Economic Data Related to Hepatorenal Syndrome at The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Diseases
The study, "The Clinical and Economic Toll Associated with Hepatorenal Syndrome from a Hospital Perspective in
"HRS is a serious condition that often requires hospitalizations and is associated with high mortality. As such, patients suffering from HRS represent a significant cost burden for the U.S. healthcare system," said
The primary cost and clinical drivers for HRS patients included length of stay, hemodialysis, and discharge to a nursing facility. Key findings include:
- Overall, the average length of stay for patients suffering from HRS was 29 days and total hospitalization cost per patient was
- During the initial hospitalization, the HRS mortality rate was 36.9 percent and an additional 8.9 percent of patients were discharged to hospice. Average cost of hospitalization for patients who died was
$106,288versus an average of $85,568for those patients who survived.
- The hospital readmission rate for patients with HRS was 28 percent, of which 12 percent were unplanned readmissions and 16 percent were planned readmissions.
- Patients with unplanned readmissions had an average total cost of care of
$92,154, compared to an average of $73,616for patients with planned readmissions.
- Using the Child-Turcotte-Pugh classification for severity of cirrhosis, the average hospitalization cost for patients with class B was
$65,122per patient, rising to $103,763for those patients with class C.
- Average cost per patient increased from
$70,676for patients with grade 1 to $112,191for patients with grade 3 as stratified by the patient's acute-on-chronic liver failure grade, which is determined by a chronic liver failure-sequential organ failure assessment.
Limitations: This study relied primarily on ICD-9 codes in the EHR; coding misclassification could lead to inaccurate case identification. Cost data were available in about one quarter (25.1 percent) of the study patients; hence cost estimates may be less complete. The study results may not be generalizable to all U.S. hospitals though CERNER HealthFacts is one of the largest EHR databases in the country, accounting for over 500 healthcare facilities across the U.S.
The poster is available on the
About Hepatorenal Syndrome
HRS is characterized by rapid, progressive functional renal failure and has a very poor prognosis, with >80 percent mortality within three months. HRS is a rare syndrome of marked renal dysfunction in patients with cirrhosis, decompensated liver disease and portal hypertension. At present, there are no approved drug therapies for HRS type 1 in the U.S. or
Senior Communications Manager
Chief Public Affairs Officer
Senior Vice President, Investor Strategy and IRO
Director, Investor Relations
View original content with multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-presents-health-economic-data-related-to-hepatorenal-syndrome-at-the-liver-meeting-2017-the-annual-meeting-of-the-american-association-for-the-study-of-liver-diseases-300541466.html